tradingkey.logo

Grail Inc

GRAL
100.070USD
+6.010+6.39%
종가 02/06, 16:00ET시세는 15분 지연됩니다
3.62B시가총액
손실P/E TTM

Grail Inc

100.070
+6.010+6.39%

자세한 내용은 Grail Inc 회사

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

Grail Inc 정보

종목 코드 GRAL
회사 이름Grail Inc
상장일Jun 12, 2024
CEORagusa (Robert)
직원 수1000
유형Ordinary Share
회계 연도 종료Jun 12
주소1525 O'brien Drive
도시MENLO PARK
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호94025
전화18336942553
웹사이트https://grail.com/
종목 코드 GRAL
상장일Jun 12, 2024
CEORagusa (Robert)

Grail Inc의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
68.19K
+6082.00%
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
48.29K
-25000.00%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
12.65K
+329.00%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
10.33K
+213.00%
Mr. Robert (Bob) Ragusa
Mr. Robert (Bob) Ragusa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Joshua (Josh) Ofman, M.D.
Mr. Joshua (Josh) Ofman, M.D.
President
President
--
--
Mr. Andy Partridge
Mr. Andy Partridge
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Steve Mizell
Mr. Steve Mizell
Independent Director
Independent Director
--
--
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--
이름
이름/직위
직위
주식 보유
변동
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
68.19K
+6082.00%
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
48.29K
-25000.00%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
12.65K
+329.00%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
10.33K
+213.00%
Mr. Robert (Bob) Ragusa
Mr. Robert (Bob) Ragusa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Joshua (Josh) Ofman, M.D.
Mr. Joshua (Josh) Ofman, M.D.
President
President
--
--

수익 분석

통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
사업별USD
이름
수익
비율
Screening
32.81M
90.64%
Development Services
3.39M
9.36%
지역별USD
이름
수익
비율
United States
32.65M
90.20%
International
3.55M
9.80%
사업별
지역별
사업별USD
이름
수익
비율
Screening
32.81M
90.64%
Development Services
3.39M
9.36%

주식 보유 통계

마지막 업데이트: Sat, Jan 31
마지막 업데이트: Sat, Jan 31
주주
주주 유형
주주
주주
비율
Illumina Inc
8.98%
BlackRock Institutional Trust Company, N.A.
5.45%
PRIMECAP Management Company
5.18%
The Vanguard Group, Inc.
5.06%
CRCM L.P.
4.62%
기타
70.71%
주주
주주
비율
Illumina Inc
8.98%
BlackRock Institutional Trust Company, N.A.
5.45%
PRIMECAP Management Company
5.18%
The Vanguard Group, Inc.
5.06%
CRCM L.P.
4.62%
기타
70.71%
주주 유형
주주
비율
Investment Advisor
26.31%
Investment Advisor/Hedge Fund
21.22%
Hedge Fund
13.43%
Corporation
8.98%
Research Firm
4.26%
Individual Investor
1.06%
Bank and Trust
0.38%
Venture Capital
0.38%
Pension Fund
0.27%
기타
23.71%

기관 주식 보유

마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
989
25.81M
66.22%
-6.45M
2025Q3
934
24.89M
69.05%
-6.05M
2025Q2
874
30.08M
83.61%
-1.68M
2025Q1
859
29.51M
82.19%
-2.62M
2024Q4
810
31.24M
92.16%
+4.27M
2024Q3
748
27.13M
81.56%
+4.49M
2024Q2
646
27.14M
86.18%
+27.14M
2024Q1
2
135.00
0.00%
+135.00

주주 활동

이름
보유 주식
비율
변동
Chg %
날짜
Illumina Inc
3.50M
8.98%
-1.00M
-22.21%
Nov 17, 2025
BlackRock Institutional Trust Company, N.A.
2.12M
5.45%
+37.64K
+1.81%
Sep 30, 2025
PRIMECAP Management Company
2.02M
5.18%
-33.35K
-1.62%
Sep 30, 2025
The Vanguard Group, Inc.
1.81M
4.64%
-85.37K
-4.50%
Sep 30, 2025
CRCM L.P.
1.80M
4.62%
-42.00K
-2.28%
Oct 06, 2025
Baker Bros. Advisors LP
1.63M
4.18%
--
--
Sep 30, 2025
Farallon Capital Management, L.L.C.
1.61M
4.13%
+232.00K
+16.85%
Nov 17, 2025
State Street Investment Management (US)
1.32M
3.38%
+69.55K
+5.58%
Sep 30, 2025
Arbiter Partners Capital Management, LLC
1.04M
2.66%
-2.00K
-0.19%
Sep 30, 2025
Sessa Capital
786.14K
2.02%
--
--
Sep 30, 2025
더 보기

관련 ETF

마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
ROBO Global Healthcare Technology & Innovation ETF
3.75%
Clough Select Equity ETF
2.7%
Clough Hedged Equity ETF
2.53%
Franklin Genomic Advancements ETF
2.49%
First Trust Small Cap Growth AlphaDEX Fund
1.08%
State Street SPDR S&P Biotech ETF
0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
0.71%
Direxion Daily S&P Biotech Bull 3X Shares
0.59%
ProShares Ultra Nasdaq Biotechnology
0.48%
Invesco RAFI US 1500 Small-Mid ETF
0.42%
더 보기
ROBO Global Healthcare Technology & Innovation ETF
비율3.75%
Clough Select Equity ETF
비율2.7%
Clough Hedged Equity ETF
비율2.53%
Franklin Genomic Advancements ETF
비율2.49%
First Trust Small Cap Growth AlphaDEX Fund
비율1.08%
State Street SPDR S&P Biotech ETF
비율0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
비율0.71%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.59%
ProShares Ultra Nasdaq Biotechnology
비율0.48%
Invesco RAFI US 1500 Small-Mid ETF
비율0.42%

주식 배당금

지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음

주식 분할

날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
KeyAI